Michael Thursby, DO
Nephrology · East Providence, RINPI 1669455192
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $200 of the $249 with a category attached, or 80.4%. Vifor Pharma, Inc. accounts for 80.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $213 and has fallen 99.8% since, to $0 in 2025. That places this record below the midpoint for nephrology clinicians in RI, where the typical reported total is $491.
Across 9 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$200
- Bayer$20
- Travere Therapeutics, Inc.$16
- GSK$13
What the payments were for
- Speaking & faculty fees$20080%
- Food & beverage$135%
- Education$3514%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 1 | $200 |
| Bayer | 1 | $20 |
| Travere Therapeutics, Inc. | 6 | $16 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
How this compares
$249 in reported general payments places this provider in the 35th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $85,271 |
| Sevelamer Carbonate | 85 | $18,269 |
| FarxigaDapagliflozin Propanediol | 13 | $9,303 |
| EliquisApixaban | 14 | $8,098 |
| Calcium Acetate | 75 | $7,067 |
| Calcitriol | 162 | $4,874 |
| Bumetanide | 50 | $3,148 |
| Potassium Citrate ErPotassium Citrate | 30 | $2,681 |
| Doxazosin Mesylate | 87 | $1,817 |
| Losartan Potassium | 146 | $1,231 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,199 |
| Amlodipine Besylate | 147 | $1,095 |
| Labetalol Hcl | 41 | $996 |
| Lisinopril | 123 | $946 |
| Allopurinol | 61 | $890 |
Paid to pharmacies, not to this prescriber.
Other nephrology in East Providence
- Larissa Kruger GomesEast Providence$4K
- Manini VishwanathEast Providence$436
- Prerna GanjooEast Providence$309
- Daniel DragomireEast Providence$278
- Christopher CosgroveEast Providence$136
- George LeeEast Providence$95
- Perola LambaEast Providence$48
- Mordecai StolkEast Providence$29
- Charles McCoyEast Providence$28
- Michael MonsourEast Providence$4
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.